Spyre Therapeutics Inc (SYRE)

Currency in USD
16.720
-0.420(-2.45%)
Closed·
16.7200.000(0.00%)
·
SYRE Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
SYRE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
16.64517.390
52 wk Range
10.91040.260
Key Statistics
Prev. Close
16.72
Open
17.18
Day's Range
16.645-17.39
52 wk Range
10.91-40.26
Volume
298.69K
Average Volume (3m)
551.52K
1-Year Change
-40.35%
Book Value / Share
4.97
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SYRE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
53.900
Upside
+222.37%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings upwards for the upcoming period

Spyre Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Spyre Therapeutics Inc Company Profile

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Compare SYRE to Peers and Sector

Metrics to compare
SYRE
Peers
Sector
Relationship
P/E Ratio
−6.2x−3.1x−0.6x
PEG Ratio
0.030.020.00
Price/Book
3.4x2.2x2.6x
Price / LTM Sales
-8.7x3.3x
Upside (Analyst Target)
243.9%172.5%39.1%
Fair Value Upside
Unlock7.4%5.4%Unlock

Analyst Ratings

12 Buy
1 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 53.900
(+222.37% Upside)

Earnings

Latest Release
Aug 05, 2025
EPS / Forecast
-0.49 / -0.7538
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

SYRE Income Statement

People Also Watch

18.34
SRPT
+1.49%
188.73
IQV
-0.04%
2.470
ABSI
-3.14%
437.17
MDGL
+2.85%
5.350
ATYR
+3.48%

FAQ

What Stock Exchange Does Spyre Therapeutics Trade On?

Spyre Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Spyre Therapeutics?

The stock symbol for Spyre Therapeutics is "SYRE."

What Is the Spyre Therapeutics Market Cap?

As of today, Spyre Therapeutics market cap is 1.01B.

What Is Spyre Therapeutics's Earnings Per Share (TTM)?

The Spyre Therapeutics EPS (TTM) is -2.85.

When Is the Next Spyre Therapeutics Earnings Date?

Spyre Therapeutics will release its next earnings report on 05 Nov 2025.

From a Technical Analysis Perspective, Is SYRE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Spyre Therapeutics Stock Split?

Spyre Therapeutics has split 1 times.

How Many Employees Does Spyre Therapeutics Have?

Spyre Therapeutics has 87 employees.

What is the current trading status of Spyre Therapeutics (SYRE)?

As of 29 Aug 2025, Spyre Therapeutics (SYRE) is trading at a price of 16.720, with a previous close of 16.72. The stock has fluctuated within a day range of 16.645 to 17.390, while its 52-week range spans from 10.910 to 40.260.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.